|
Autoantibodies and drug-induced lupus under infliximab |
|||||||||
| New ANA |
New anti-dsDNA |
New ACLA |
|||||||
|
|
|
|
|||||||
| Diagnosis |
Number |
Positive |
Positivea |
IgM |
IgG |
IgM |
IgG |
DIL |
Reference |
|
|
|||||||||
| RA |
156 |
37 (24%) |
22 (14%) |
22 |
1 |
ND |
ND |
1 |
[20] |
| RA |
62 |
19 (31%) |
7 (11%) |
7 |
0 |
ND |
ND |
0 |
[22] |
| RA |
24 |
4 (17%) |
13 (54%) |
9–11 |
3–4 |
5 |
0 |
0 |
[24] |
| RA |
59 |
24 (41%) |
21 (36%) |
19 |
2 |
ND |
ND |
0 |
[26] |
| RA |
53 |
29 (55%) |
5 (9%) |
22b |
34b |
0 |
0 |
2 |
[27] |
| RA |
59 |
24 (41%) |
29 (49%) |
28 |
1 |
0 |
0 |
0 |
[28] |
| RA |
57 |
28 (49%) |
ND |
3 |
ND |
ND |
1 |
[31] |
|
| All RA |
413 |
165 (40%) |
77 (19%) |
4 (1.0%) |
|||||
| AS |
15 |
9 (60%) |
4 (27%) |
4 |
0–1 |
1 |
3 |
0 |
[24] |
| SpA |
21 |
12 (57%) |
4 (19%) |
ND |
ND |
ND |
ND |
0 |
[21] |
| SpA |
35 |
25 (71%) |
6 (17%) |
6 |
0 |
ND |
ND |
0 |
[22] |
| SpA |
33 |
8 (24%) |
11 (33%) |
11 |
0 |
ND |
ND |
0 |
[29] |
| All SpA |
94 |
54 (57%) |
25 (27%) |
0 (0%) |
|||||
| CD |
35 |
6 (17%) |
3 (9%) |
ND |
ND |
ND |
ND |
0 |
[23] |
| CD |
125 |
71 (57%) |
14 (11%) |
ND |
ND |
ND |
ND |
2 |
[25] |
| CD |
500 |
ND |
ND |
ND |
ND |
ND |
ND |
3 |
[35] |
| CD |
63 |
21 (33%) |
9 (14%) |
ND |
9 |
2 |
0 |
1 |
[30] |
| All CD |
723 |
6 (0.8%) |
|||||||
| All together |
1,230 |
10 (0.8%) |
|||||||
|
aRadioimmunoassay or most conservative value reported; bvalues difficult to reconcile with the number of patients with anti-dsDNA antibodies as measured by radioimmunoassay. ACLA, anti-cardiolipin antibodies; ANA, anti-nuclear antibodies; anti-dsDNA, antibodies to double-stranded DNA; AS, ankylosing spondylitis; CD, Crohn disease; DIL, drug-induced lupus; Ig, immunoglobulin; ND, not determined/reported; RA, rheumatoid arthritis; SpA, spondylarthropathies. | |||||||||
Aringer and Smolen Arthritis Research & Therapy 2008 10:202 doi:10.1186/ar2341 |
|||||||||